Byambaa Suvd

研究分野 (1件)：分子生物学

研究キーワード (3件)：再生医学 , 遺伝子治療 , ゲノム編集

論文 (3件)：

Suvd Byambaa, Hideki Uosaki, Tsukasa Ohmori, Hiromasa Hara, Hitoshi Endo, Osamu Nureki, Yutaka Hanazono. Non-viral ex vivo genome-editing in mouse bona fide hematopoietic stem cells with CRISPR/Cas9. Molecular therapy. Methods & clinical development. 2021. 20. 451-462
Suvd Byambaa, Hideki Uosaki, Tsukasa Ohmori, Hiromasa Hara, Hitoshi Endo, Osamu Nureki, Yutaka Hanazono. Non-viral ex vivo genome-editing in mouse bona fide hematopoietic stem cells with CRISPR/Cas9. Molecular Therapy - Methods & Clinical Development. 2021. 20. 451-462
Suvd Byambaa, Hideki Uosaki, Hiromasa Hara, Yasumitsu Nagao, Tomoyuki Abe, Hiroaki Shibata, Osamu Nureki, Tsukasa Ohmori, Yutaka Hanazono. Generation of novel Il2rg-knockout mice with clustered regularly interspaced short palindromic repeats (CRISPR) and Cas9. Experimental animals. 2020. 69. 2. 189-198

MISC (1件)：

Suvd Byambaa, Hideki Uosaki, Hiromasa Hara, Tomoyuki Abe, Yasumitsu Nagao, Osamu Nureki, Tsukasa Ohmori, Yutaka Hanazono. Resistance of Mouse Hematopoietic Stem and Progenitor Cells to the Genome-Editing with Cas9. MOLECULAR THERAPY. 2017. 25. 5. 93-93

講演・口頭発表等 (9件)：

Phenotypical Correction of X-SCID Mice After CRISPR/Cas9-mediated UNIVERSAL Genome-Editing Therapy of Hematopoietic Stem Cells
(Frontiers in Genome Engineering 2019)
Phenotypical Correction of X-SCID Mice After CRISPR/Cas9-mediated Genome-Editing Therapy of Hematopoietic Stem Cells
(JSGCT 2019)
Genome Editing of Murine Hematopoietic Stem Cells by Cas9/RNP Targeting Integrin-alpha IIb Gene
(JSGE 2019)
Cure of X-SCID Mice After Ex Vivo Non-viral Genome-Editing Therapy of Hematopoietic Stem Cells
(ASGCT 2019)
Targeted Gene Integration in Hematopoietic Stem and Progenitor Cells with Cas9-RNP Method to Universally Correct X-SCID Mutations
(第41回日本分子生物学会年会 2018年11月30日 2018)

学歴 (1件)：

経歴 (2件)：

受賞 (2件)：

※　J-GLOBALの研究者情報は、researchmapの登録情報に基づき表示しています。登録・更新については、こちらをご覧ください。